The article you were looking is not available for one of the reasons below:
This article has been declined for editorial reasons, the author has been notified and we are awaiting their edits.
This article has been modified and is awaiting editorial response
This article has been removed from our database as it contains inappropriate content.
Below you will find more articles that we hope you find relevant
Amgen (amgn) Global Health Economics And Outcomes Research By: mikeguth | Oct 9th 2007 - Amgen's pharmaceutical economics modeling and data manipulations seem dubious, and it appears ethically questionable to analyze data with the intended goal of proving an Amgen drug rejected in clinical trials has some medical benefit that doctors in the field overlooked. Tags:health economics, outcomes research, Amgen, AMGN, pharmaceutical, drug, clinical trial, Novartis, Zometa, think outside the box
